VERISILICON
21.9.2023 05:09:27 CEST | Business Wire | Press release
VeriSilicon (688521.SH) today announced that Inuitive, a leading vision-on-chip processor company, has adopted its dual-channel Image Signal Processor (ISP) IP, featuring low latency and low power capabilities, into its mass-produced NU4100 vision AI processor. This integration brings outstanding imaging and vision experience to Robots, Augmented Reality (AR), Virtual Reality (VR), Mixed Reality (MR), Drones, and many other applications.
Inuitive’s NU4100 is a highly-integrated single-chip with high-quality 3D depth sensing, enhanced AI processing and on-chip VSLAM (Visual Simultaneous Localization and Mapping) capabilities. It can process large volumes of data from multiple 4K resolution cameras with low latency and low power consumption. As a powerful vision processor, it introduces an optimized embedded vision architecture that effectively combines a set of computing blocks including computer vision engine and deep learning (CNN) processing.
VeriSilicon’s ISP provides high throughput processing capability, catering to a wide range of applications for the NU4100 vision AI processor. It supports multiple cameras with multi-context management, HDR (High Dynamic Range), advanced noise reduction, and more, greatly enhancing the overall performance of the vision processor.
Dor Zepeniuk, CTO at Inuitive, says, “Our NU4100 high-performance vision AI processor has set a new benchmark in the industry with a unique set of combined 3D vision, AI and VSLAM capabilities. We greatly value VeriSilicon’s advanced technologies and services, and are working closely with them on roadmap processors to provide ultimate single-chip solutions for Robotics and various applications, addressing key vision challenges in the industry.”
Wei-Jin Dai, Executive VP and GM of IP Division at VeriSilicon, says, “Robotics and AR/VR/MR applications represent the forefront of innovation driven by progressive technologies. With our comprehensive Glass to Glass intelligent pixel processing IP portfolio, and IP subsystems which leverage our unique FLEXA technology that delivers short latency from sight to video and AI processing, VeriSilicon will actively innovate in these fields through collaborations with our partners like Inuitive.”
About Inuitive
Inuitive’s disruptive Vision-on-Chip processors introduce all-in-one chips with a wide range of integrated capabilities, outstanding performance, optimal size, and cost efficiency. These game-changing processors support simultaneous depth sensing, positioning, location algorithms (SLAM), and AI-based object detection and recognition while dramatically shortening both system latency and response time, saving power and improving overall performance (high frame rate and camera resolution, and a wide FOV).
Together with its technological ecosystem of partners in the field of machine sensing, software development, and commercial manufacturing, Inuitive integrates its enterprise-ready sensor-and-processor modules into its customers’ robotics, drones, AR, VR, MR, AIoT, and 3D sensing applications, providing human-like visual understanding with optimal capabilities and superior performance.
For more information, please visit www.inuitive-tech.com.
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230920245013/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom